About 16 results found for searched term "AR-42" (0.052 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1661 | AZD6244 | MEK |
| Selumetinib, ARRY-142886 | ||
| AZD6244 (ARRY-142886, Selumetinib) is a potent MEK 1/2 inhibitor with GI50 values ranging from 14 to 50 nM. | ||
| M1662 | AZD8330 | MEK |
| ARRY-424704, ARRY-704 | ||
| AZD8330 (ARRY-424704) is a novel, selective, highly efficacious, uncompetitive MEK inhibitor with an IC50 of 7 nM. | ||
| M2468 | Brimonidine Tartrate | Adrenergic Receptor |
| Brimonidine tartrate; AGN190342 tartrate; UK14304 tartrate | ||
| Brimonidine Tartrate is a highly selective α-adrenergic receptor antagonist with an EC50 of 0.45 nM for α2A adrenoreceptor, and has been used to study open-angle glaucoma or ocular hypertension. | ||
| M3405 | AR-42 | HDAC |
| OSU-HDAC42; HDAC-42 | ||
| AR-42 is an HDAC inhibitor with IC50 of 30 nM. AR-42 induces growth inhibition, cell-cycle arrest, apoptosis, and activation of caspases-3/7. AR-42 promotes hyperacetylation of H3, H4, and alpha-tubulin, and up-regulation of p21. | ||
| M3440 | Nilvadipine | Calcium Channel |
| ARC029, FR34235 | ||
| Nilvadipine is a potent calcium channel blocker with an IC50 of 0.03 nM. | ||
| M6182 | 7ACC1 | Monocarboxylate Transporter (MCT) |
| DEAC; Coumarin D 1421; D 1421 | ||
| 7ACC1(DEAC; Coumarin D 1421; D 1421) selectively interfere with lactate fluxes in the lactate-rich tumor microenvironment; inhibits lactate influx but not efflux in tumor cells expressing MCT1 and MCT4 transporters. | ||
| M6454 | AR420626 | GPR/FFAR |
| AR-420626 | ||
| AR420626 is a selective agonist of free fatty acid receptor 3 (FFAR3, GPR41) with IC50 of 117 nM. | ||
| M10274 | Tolebrutinib | BTK |
| SAR442168; PRN2246 | ||
| Tolebrutinib (SAR442168) is a potent, selective, orally active and blood-brain barrier capable bruton's tyrosine kinase (BTK) inhibitor with IC50 values of 0.4 and 0.7 nM in Ramos B cells and HMC microglia, respectively. Tolebrutinib has an effect on central nervous system immunity. Tolebrutinib can be used in multiple sclerosis (MS) studies. | ||
| M14171 | Selumetinib sulfate | MEK |
| AZD6244 sulfate; ARRY-142886 sulfate | ||
| Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation. | ||
| M45149 | Vari Fluor 425 SE | Fluorescent Dye |
| VF 425 SE | ||
| Vari Fluor 425 SE is a Vari Fluor SE series labeling dye (Ex/Em=430 nm/475 nm).The Vari Fluor SE series dyes are a class of fluorescent dyes that contain NHS ester groups for labeling antibodies, proteins, peptides, amine-modified oligonucleotides, and free amines (-NHX) on other biomolecules. | ||
| M49407 | Fipaxalparant | LPL Receptor |
| SAR-100842; HZN-825 | ||
| Fipaxalparant is a potent, orally active and selective LPA1 receptor antagonist for studies related to idiopathic pulmonary fibrosis (IPF). | ||
| M52474 | Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42) | Amyloid |
| Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). | ||
| M53534 | Epstein-barr virus BRLF1 (134-142) | Anti-infection |
| Epstein-barr virus BRLF1 (134-142) is a biological active peptide. | ||
| M54591 | SAR-442501 | FGFR |
| SAR-442501 is a novel anti-FGFR3 monoclonal antibody for studies related to achondroplasia (ACH). | ||
| M55240 | SAR-442970 | TNF Receptor |
| SAR 442970 is an anti tumour necrosis factor alpha (TNFα) and OX40 ligand (OX40L) molecule. | ||
| M4879 | Cycloheximide | DNA/RNA Synthesis |
| Naramycin A; Actidione; CHX; FT 3422-2; NM-MCD 80 | ||
| Cycloheximide (Naramycin A) is an inhibitor of protein biosynthesis in eukaryotic organisms, with IC50 of 532.5 nM. Cycloheximide binds to the E-site of the 60S subunit of the ribosome during the protein synthesis process in eukaryotic cells, blocking the ribosome translocation process mediated by eEF2 and preventing the synthesis of new proteins. Cycloheximide suppresses ferroptosis and inhibits autophagy. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
